Eylea vs Vabysmo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Eylea | US Vabysmo | |
|---|---|---|
| Generic name | aflibercept | faricimab |
| Drug class | VEGF Inhibitor (Eye Injection) | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) |
| Treats | Wet macular degeneration, diabetic eye disease | Wet macular degeneration, diabetic macular edema |
| Category | Eye Health | Eye Health |
| Manufacturer | Regeneron | Genentech (Roche) |
| Year approved | 2011 | 2022 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $90M | $85M |
| Common side effects | Eye floaters, Eye pain, Increased eye pressure, Bleeding in the eye | Eye inflammation, Floaters, Increased eye pressure, Blurred vision |
Frequently asked questions
Is Eylea or Vabysmo better?
Neither is universally "better." Eylea (aflibercept) and Vabysmo (faricimab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eylea and Vabysmo?
Eylea is a VEGF Inhibitor (Eye Injection) made by Regeneron, while Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eylea has the larger estimated TV advertising budget of the two.